Skip to main content

Advertisement

SpringerLink
Log in

Results of intravitreal triamcinolone acetonide in patients with macular edema secondary to branch retinal vein occlusion

  • Research Article
  • Published:
International Journal of Clinical Pharmacy Aims and scope Submit manuscript

Abstract

Background Macular edema is one of the most common causes of visual loss in patients with retinal vein oclusions. Intravitreal corticosteroids and intravitreal anti-vascular endothelial growth factors are modalities of treatment for macular edema secondary to branch retinal vein occlusion (BRVO). Objective To present the results of intravitreal triamcinolone acetonide therapy in patients with macular edema secondary to BRVO. Setting A retrospective clinical interventional study included 32 patients with macular edema secondary to BRVO. Method The records of 32 eyes of 32 patients who received 4 mg/0.1 mL injection of intravitreal triamcinlone for macular edema secondary to BRVO were evaluated. Patients with visual acuity <0.40 logMAR (logarithm of the minimum angle of resolution), central macular thickness (CMT) >260 μm and no neovascularization at baseline were included. Patients with diabetes mellitus, a history of intravitreal anti vascular endothelial growth factor injection, grid laser photocoagulation and ischemic BRVO were excluded. The re-injections were performed in cases with increased CMT >100 μm or vision loss of five or more letters. Results The mean follow-up was 12 ± 1.9 months. The visual acuity increased from 0.58 ± 0.16 at baseline to 0.25 ± 0.11 logMAR (P < 0.001). The CMT decreased from 490 ± 107 μm at baseline to 266 ± 90 μm at 12 months (P < 0.001). Both cataract and glaucoma developed in 18.75 % patients. Conclusion Intravitreal triamcinolone, due to absence of systemic side effects, can be used with confidence for treatment macular edema secondary to BRVO. However the main disadvantages of intravitreal triamcinolone injection are elevation of intraocular pressure and formation of cataract.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Cugati S, Wang JJ, Rochtchine E, Mitchell P. Ten-year incidence of retinal vein occlusion in an older population: the Blue Mountain Eye study. Arch Ophthalmol. 2006;124(5):726–32.

    Article  PubMed  Google Scholar 

  2. Hayreh SS, Zimmerman B, Mc Carthy MJ, Podhajsky P. Systemic diseases associated with various types of retinal occlusion. Am J Ophthalmol. 2001;131(1):61–77.

    Article  CAS  PubMed  Google Scholar 

  3. Blond J, Glacet-Bernard A, Bayani N, Blacher J, Lelong F, Nordmann JP, et al. Retinal vein occlusion and hyperhomocysteinemia. J Fr Opthalmol. 2003;26(3):249–53.

    Google Scholar 

  4. Rath EZ, Frank RN, Shin DH, Kim C. Risk factors for retinal vein occlusion. A case–control study. Ophthalmology. 1992;99(4):509–14.

    Article  CAS  PubMed  Google Scholar 

  5. Aref AA, Scott IU. Management of macular edema secondary to branch retinal vein occlusion: an evidence-based update. Adv Ther. 2011;28(1):28–39.

    Article  PubMed  Google Scholar 

  6. Cheng KC, Wu WC, Chen KJ. Intravitreal triamcinolone acetonide vs bevacizumab for treatment of macular oedema secondary to branch retinal vein occlusion. Eye (Lond). 2009;23(11):2023–33.

    Article  CAS  Google Scholar 

  7. Higashiyama T, Sawada O, Kakinoki M, Sawada T, Kawamura H, Ohji M. Prospective comparisons of intravitreal injections of triamcinolone acetonide and bevacizumab for macular oedema due to branch retinal vein occlusion. Acta Ophthalmol. 2013;91(4):318–24.

    Article  CAS  PubMed  Google Scholar 

  8. Aiello LP, Avery RL, Arrig PG, Keyt BA, Jampel HD, Shah ST, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994;331(22):1480–7.

    Article  CAS  PubMed  Google Scholar 

  9. Funk M, Kriechbaum K, Prager F, Benesch T, Georgopoulos M, Zlabinger GJ, et al. Intraocular concentrations of growth factors and cytokines in retinal vein occlusion and the effect of therapy with bevacizumab. Investig Ophthalmol Vis Sci. 2009;50(3):1025–32.

    Article  Google Scholar 

  10. Kaneda S, Miyazaki D, Sasaki S, Yakura K, Terasaka Y, Miyake K, et al. Multivariate analyses of inflammatory cytokines in eyes with branch retinal vein occlusion: relationships to bevacizumab treatment. Investig Ophthalmol Vis Sci. 2011;52(6):2982–8.

    Article  CAS  Google Scholar 

  11. Noma H, Funatsu H, Yamasaki M, Tsukamoto H, Mimura T, Sone T, et al. Aqueous humour levels of cytokines are correlated to vitreous levels and severity of macular oedema in branch retinal vein occlusion. Eye (Lond). 2008;22(1):42–8.

    Article  CAS  Google Scholar 

  12. Branch Retinal Vein Occlusion Study Group. Argon laser photocoagulation for macular edema in branch vein occlusion. Am J Ophthalmol. 1984;98(3):271–82.

    Google Scholar 

  13. Akduman L, Olk RJ. Subthreshold (invisible) modified grid diode laser photocoagulation in diffuse diabetic macular edema (DDME). Ophthal Surg Lasers. 1999;30(9):706–14.

    CAS  Google Scholar 

  14. Channa R, Smith M, Campochiaro PA. Treatment of macular edema due to retinal vein occlusions. Clin Ophthalmol. 2010;5:705–13.

    Google Scholar 

  15. Holladay JT. Visual acuity measurements. J Cataract Refract Surg. 2004;30(2):287–90.

    Article  PubMed  Google Scholar 

  16. Demir M, Oba E, Gulkilik G, Odabasi M, Ozdal E. Intravitreal bevacizumab for macular edema due to branch retinal vein occlusion: 12-month results. Clin Ophthalmol. 2011;5:745–9.

    Article  PubMed Central  PubMed  Google Scholar 

  17. Kriechbaum K, Michels S, Prager F, Georgopoulos M, Funk M, Geitzenauer W, et al. Intravitreal Avastin for macular oedema secondary to retinal vein occlusion: a prospective study. Br J Ophthalmol. 2008;92(4):518–22.

    Article  CAS  PubMed  Google Scholar 

  18. Byun YJ, Roh MI, Lee SC, Koh HJ. Intravitreal triamcinolone acetonide versus bevacizumab therapy for macular edema associated with branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol. 2010;248(7):963–71.

    Article  CAS  PubMed  Google Scholar 

  19. Carneiro AM, Barthelmes D, Falcao MS, Mendonca LS, Fonseca SL, Goncalves RM, et al. Arterial thromboembolic events in patients with exudative age-related macular degeneration treated with intravitreal bevacizumab or ranibizumab. Ophthalmologica. 2011;225(4):211–21.

    Article  CAS  PubMed  Google Scholar 

  20. Ding X, Li J, Hu X, Yu S, Pan J, Tang S. Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion. Retina. 2011;31(5):838–45.

    Article  CAS  PubMed  Google Scholar 

  21. Tao Y, Hou J, Jiang YR, Li XX, Jonas JB. Intravitreal bevacizumab vs triamcinolone acetonide for macular oedema due to central retinal vein occlusion. Eye (Lond). 2010;24(5):810–5.

    Article  CAS  Google Scholar 

  22. Cekic O, Cakır M, Yazıcı AT, Alagöz N, Bozkurt E, Faruk OF. A comparison of three different intravitreal treatment modalities of macular edema due to branch retinal vein occlusion. Curr Eye Res. 2010;35(10):925–9.

    Article  CAS  PubMed  Google Scholar 

  23. Cakir M, Dogan M, Bayraktar Z, Bayraktar S, Acar N, Altan T, et al. Efficacy of intravitreal triamcinolone for the treatment of macular edema secondary to branch retinal vein occlusion in eyes with or without grid laser photocoagulation. Retina. 2008;28(3):465–72.

    Article  PubMed  Google Scholar 

  24. Noma H, Funatsu H, Mimura T, Shimada K. Functional-morphological changes after ıntravitreal ınjection of triamcinolone acetonide for macular edema with branch retinal vein occlusion. J Ocul Pharmacol Ther. 2012;28(3):231–6.

    Article  CAS  PubMed  Google Scholar 

  25. Chen SD, Sundaram V, Lochhead J, Patel CK. Intravitreal triamcinolone for the treatment of ischemic macular edema associated with branch retinal vein occlusion. Am J Ophthalmol. 2006;141(5):876–83.

    Article  CAS  PubMed  Google Scholar 

  26. Vasconcelos-Santos DV, Nehemy PG, Schachat AP, Nehemy MB. Secondary ocular hypertension after intravitreal injection of 4 mg of triamcinolone acetonide: incidence and risk factors. Retina. 2008;28(4):573–80.

    Article  PubMed  Google Scholar 

  27. Prager F, Michels S, Kriechbaum K, Georgopoulos M, Funk M, Geitzenauer W, Polak K, et al. Intravitreal bevacizumab (Avastin) for macular oedema secondary to retinal vein occlusion: 12-month results of prospective clinical trial. Br J Ophthalmol. 2009;93(4):452–6.

    Article  CAS  PubMed  Google Scholar 

  28. Ahmadi AA, Chuo JY, Banashkevich A, Ma PE, Maberley DA. The effects of intravitreal bevacizumab on patients with macular edema secondary to branch retinal vein occlusion. Can J Ophthalmol. 2009;44(2):154–9.

    Article  PubMed  Google Scholar 

  29. Kim JY, Park SP. Comparison between intravitreal bevacizumab and triamcinolone for macular edema secondary to branch retinal vein occlusion. Korean J Ophthalmol. 2009;23(4):259–65.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  30. Hou J, Tao Y, Jiang YR, Li XX, Gao L. Intravitreal bevacizumab versus triamcinolone acetonide for macular edema due to branch retinal vein occlusion: a matched study. Chin Med J (Engl). 2009;122(22):2695–9.

    CAS  PubMed  Google Scholar 

  31. Rezende MP, Dias AF, Oshima A, Andrade EP, Serracarbassa PD. Study of visual acuity and intraocular pressure in the treatment of macular diabetic edema with intravitreous triamcinolone. Arq Bras Oftalmol. 2010;73(2):129–34.

    Article  PubMed  Google Scholar 

  32. Gillies MC, Islam FM, Larsson J, Pasadhika S, Gaston C, Zhu M, et al. Triamcinolone-induced cataract in eyes with diabetic macular oedema: 3-year prospective date from a randomised clinical trial. Clin Exp Ophthalmol. 2010;38(6):605–12.

    Article  Google Scholar 

  33. Islam MS, Vernon SA, Negi A. Intravitreal triamcinolone will cause posterior subcapsular cataract in most eyes with diabetic maculopathy within 2 years. Eye (Lond). 2007;21(3):321–3.

    Article  CAS  Google Scholar 

  34. Hanada N, Iijima H, Sakurada Y, Imasawa M. Recurrence of macular edema associated with branch retinal vein occlusion after intravitreal bevacizumab. Jpn J Ophthalmol. 2012;56(2):165–74.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

The authors would like to thank the clinical secretaries for their assistance.

Funding

None.

Conflicts of interest

The authors declare that they have no conflicts of interest.

Author information

Authors and Affiliations

  1. Department of Ophthalmology, Sisli Etfal Training and Research Hospital, Halaskargazi caddesi Etfal sokak, Etfal Hastanesi, 34400, Istanbul, Turkey

    Mehmet Demir, Dilek Guven, Zeynep Acar & Sonmez Cinar

  2. Department of Ophthalmology, Kafkas University, 36000, Kars, Turkey

    Ersin Oba

Authors
  1. Mehmet Demir
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ersin Oba
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dilek Guven
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Zeynep Acar
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Sonmez Cinar
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mehmet Demir.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Demir, M., Oba, E., Guven, D. et al. Results of intravitreal triamcinolone acetonide in patients with macular edema secondary to branch retinal vein occlusion. Int J Clin Pharm 36, 438–442 (2014). https://doi.org/10.1007/s11096-014-9918-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11096-014-9918-9

Keywords

Search

Navigation